$V — AVOID 📊 | 6 MONTHS THESIS

$V — AVOID 📊 | 6 MONTHS THESIS 🎯 Q1 2026 | Rev $11.2B | EPS $3.31 vs $3.10 🟢 | Margin 64.4% 💡 Consensus expects steady mid-teens growth and a premium valuation; my variant view is that the beat was already anticipated (the stock did not gap up meaningfully post-report) and that no incremental driver exists to push the stock higher, making downside risk from any disappointment more likely. 📉 Reward/risk: 1.08:1 🏢 Business Quality: 9/10 📊 Valuation: rich — P/E ~28x forward vs sector median ~14x; EV/EBITDA ~20x vs sector ~12x; DCF with generous assumptions yields only mid-single-digit upside. 🔮 Catalyst: None expected 💰 Entry: $334.22, stop $310, target $360 ⚖️ Avoid Visa at $334; the Q1 beat is old news, valuation is stretched, and no catalyst exists to drive outperformance over the next three months. 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/V0625

🎯 Q1 2026 | Rev $11.2B | EPS $3.31 vs $3.10 🟢 | Margin 64.4%